A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON ® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
RecruitingCTIS2023-507030-24-00
Glaukos Corp.Persistent Corneal Epithelial Defects
Start: 2025-04-30Target: 60Updated: 2026-01-26